Senores Pharmaceuticals IPO listing date: All you need to know before debut on NSE and BSE

Senores Pharmaceuticals Listing Date: Shares of Senores Pharmaceuticals are set to be listed on the stock exchanges on Monday, December 30, after investors responded strongly during the three-day bidding period.

Ahead of the listing, here are key things you should note.

Senores Pharmaceutials IPO: Subscription

The initial public offer was subscribed 93.69 times as it received bids for 79.95 crore shares against 85.34 lakh shares on offer.

Non-institutional investors (NIIs) led the demand as their portion was booked 96.30 times. They bid for 22.33 crore shares against 23.19 lakh shares on offer.

Qualified institutional buyers (QIBs) mopped up 94.66 times the subscription, securing bids for 43.47 crore shares compared to 45.93 lakh shares reserved.

Retail investors placed bids for 13.99 crore shares compared to 15.46 lakh shares offered, leading to 90.46 times subscription.

Senores Pharmaceuticals IPO: Objectives

The ₹582.11 crore IPO was a fresh issuance of equity shares valued at ₹500 crore and an offer-for-sale worth ₹82.11 crore. The lot size was 38 shares, requiring an investment of ₹14,858.

The net proceeds from the fresh issue will be used for the following purposes:

• Invest in a subsidiary, Havix, to fund capital expenditures needed to set up a manufacturing plant for the production of sterile injections at the Atlanta Facility.
• Debt payment of the company
• Clear debt of subsidiary Havix
• Fund working capital requirements
• Invest in subsidiaries SPI and Ratnatris to fund their working capital needs
• Fund inorganic growth via acquisition and strategic initiatives
• General corporate purposes.

Senores Pharmaceuticals IPO listing date and time

Shares of Senores Pharmaceuticals will be listed on the National Stock Exchange (NSE) and the BSE on Monday, December 30 at 10 am.

Senores Pharmaceuticals financials

About Senores Pharmaceuticals

Senores Pharmaceuticals develops and manufactures a variety of pharmaceutical products for regulated markets in the United States, Canada and the United Kingdom.

The company operates through two business modes: contract development and manufacturing operations (CDMO) and marketed products (ANDA products and sourced products). Of the overall revenue, marketed products contribute 90.05%, while the remaining comes from the CDMO segment.